Helus Pharma reported positive topline results Monday from its first Phase 3 trial of HLP003, a deuterated psilocin product being developed as an adjunctive treatment for major depressive disorder.

The 222-patient APPROACH study met its primary endpoint at six weeks and its key secondary endpoint at 12 weeks, with response and remission rates roughly double those on placebo. The company said the drug was generally well tolerated, with most side effects mild to moderate and concentrated on the dosing day.

The stock fell anyway. Shares dropped about 20% in premarket trading, according to Reuters, a reaction that suggests the result did not clear the bar investors had set for the first of three planned Phase 3 studies.

What HLP003 is

HLP003 is a proprietary serotonergic agonist built on psilocin, the active metabolite of psilocybin. The deuterated form is designed to change how the molecule is broken down in the body, which can extend its effects or reduce variability between patients. The company describes the class as activating serotonin pathways believed to promote neuroplasticity.

It is not a standard antidepressant. HLP003 is given as an adjunct to an existing antidepressant regimen, not instead of one, and the trial enrolled patients whose depression had not fully responded to their current treatment. The FDA has granted Breakthrough Therapy Designation for the adjunctive major depressive disorder use. The drug remains investigational.

Helus is a clinical-stage company listed on Nasdaq and Cboe Canada under the ticker HELP. Its pipeline includes HLP004 for generalized anxiety disorder in Phase 2 and the PARADIGM program for depression. Breakthrough Therapy Designation, which the FDA grants when early evidence suggests a drug may offer a substantial improvement over existing therapies, gives the program more frequent agency meetings and a potential priority review, though it does not change the requirement for two adequate and well-controlled trials.

Major depressive disorder is one of the most common conditions in medicine, and current treatments leave a large share of patients without full relief. Standard antidepressants can take weeks to work, and many patients cycle through several before finding one that helps. That gap is why the psychedelic class has attracted so much attention: the promise is a faster, larger effect in people who have not responded to the standard course. The evidence has been promising but uneven, and the field has learned to be cautious about single-site results and open-label extensions.

The data

APPROACH randomized 222 adults with moderate or severe major depressive disorder, defined as a Montgomery-Asberg Depression Rating Scale score of at least 24 at screening and baseline. All patients continued stable antidepressant treatment. The trial assigned 112 to HLP003 and 110 to placebo, double-blind.

The primary endpoint was the change in MADRS score at week 6. HLP003 produced a least-squares mean reduction of 19.5 points against 11.9 for placebo, a 7.6-point advantage with a p value below 0.0001 and an effect size of 0.653.

At week 12, the advantage held: 16.9 points of reduction against 9.9, a 7.0-point difference with an effect size of 0.581. Separation from placebo was visible as early as day 2, when the drug showed a 5.0-point advantage.

The response and remission numbers were the most striking part of the release. At week 6, 56.3% of patients on HLP003 had at least a 50% reduction in symptoms, against 28.2% on placebo. Remission, defined as a MADRS score of 10 or below, was 50.9% against 18.2%. At week 12, response was 45.5% against 19.1% and remission 40.2% against 15.5%. All of those comparisons carried p values of 0.0002 or lower.

To read those numbers, it helps to know the scale. The MADRS is a 10-item clinician-rated measure scored from 0 to 60, with higher scores meaning more severe depression; remission is conventionally a score of 10 or below. A 7.6-point placebo-adjusted difference is large for a depression trial. Many standard antidepressant trials in mild-to-moderate populations report differences of two to three points, though cross-trial comparisons are unreliable because the populations, baselines, and raters differ. The effect size of 0.653 is in the moderate-to-large range.

Dr. Roger McIntyre of the University of Toronto called the benefit "highly compelling" in the company's release.

The design makes the result stronger than much of the earlier evidence. APPROACH is multicenter, randomized, double-blind, and placebo-controlled, with a prespecified primary endpoint. The effect separated from placebo by day 2 and persisted at 12 weeks, which addresses two common criticisms of the earlier literature: that the effects are transient and that they depend on the expectancy of patients who know they are receiving a psychedelic.

Safety and the parts that are not in the headline

The company said most adverse events were mild to moderate, transient, and occurred mainly on the day of dosing, which is consistent with the profile of serotonergic psychedelics. Three treatment-related serious adverse events were attributed to HLP003. The release does not describe them in detail, and the full dataset will be presented at a medical meeting and submitted for publication.

That is the part clinicians will want to see. A drug that produces a large average benefit but also produces serious events in a small number of patients can look different in practice than it does in a topline release. The same is true of the dosing-day experience: psychedelic compounds can produce perceptual distortions, anxiety, or blood-pressure changes, and the trial's safety monitoring will matter as much as the efficacy numbers.

The company also has not yet shown how the drug performs over a full year, whether patients need repeat dosing, or how it interacts with the full range of antidepressants. EXTEND, a long-term extension study, is designed to answer some of those questions.

Blinding is the other issue. A placebo cannot reproduce the perceptual effects of a serotonergic psychedelic, so patients and raters may be able to guess who received the drug. That phenomenon, known as functional unblinding, can inflate the apparent effect. Helus ran APPROACH double-blind, but the release does not describe how it protected the blind. The full paper will be the place to look.

Why the stock fell

A 7.6-point placebo-adjusted improvement on the MADRS is a large effect for a depression trial. The remission rate, roughly 51% against 18%, is the kind of number that usually moves a biotech stock up. The shares moved down instead.

The reporting does not give a single reason, and the company's release does not address the reaction. Several explanations are plausible. Investors may have expected a larger effect or a cleaner safety profile. They may be focused on the three serious adverse events. They may be looking ahead to EMBRACE, the second Phase 3 trial, and wondering whether the result will replicate. Or the stock may have run up into the readout and sold off on the news, a pattern that has nothing to do with the data.

What the reaction does not change is the trial result. APPROACH is a positive, well-powered Phase 3 study with a durable effect at 12 weeks. The market's judgment about what that is worth is a separate question. The selloff also came on the same morning as the company's quarterly financial results, which gave investors a second set of numbers to weigh.

The regulatory path

Helus is running APPROACH as the first of three Phase 3 studies in its PARADIGM program. EMBRACE, the second pivotal trial, is ongoing and expected to read out in the fourth quarter of 2027. EXTEND, the long-term extension, will follow patients from both studies.

That timeline matters. Even if EMBRACE succeeds, a filing and review would put a potential approval in 2028 or later. The company's Breakthrough Therapy Designation can speed parts of the process, but it does not replace the second trial.

Helus is also developing HLP004 for generalized anxiety disorder in Phase 2, a separate program that gives the company a second shot if the depression path slows.

The field

Psychedelic depression research has spent years oscillating between excitement and disappointment. The promise is a rapid, large effect in patients who have not responded to standard treatment. The problem is that the results have been hard to reproduce at scale, and the regulatory path is complicated by the dosing experience, the need for supervised administration, and the difficulty of blinding patients to a drug that produces obvious perceptual effects.

Compass Pathways has been developing COMP360, a synthetic psilocybin product, for treatment-resistant depression. Helus is targeting a different population, adjunctive treatment of moderate-to-severe depression, which is larger and less severely ill.

APPROACH is a meaningful data point for the field because it is a large, randomized, placebo-controlled trial with a durable effect. The caveats are the ones that always apply to a single study: the population, the site selection, the dosing protocol, and the integrity of the blind.

The dosing model is another difference from a standard antidepressant. Psilocybin-derived drugs are typically given in a supervised session, with monitoring and psychological support, and the patient stays at the site for hours. That model is not unprecedented: esketamine for treatment-resistant depression is administered under a restricted program at certified sites. But it requires clinics, trained staff, and a payment pathway, which are part of the commercial risk as much as the clinical one.

What to watch

The full APPROACH dataset, including the serious adverse events and the details of the blinding, will matter more than the topline. EMBRACE will determine whether the effect replicates. EXTEND will show whether the benefit lasts and whether patients need to be dosed again.

For patients, nothing changes yet. HLP003 is investigational, not approved, and not available by prescription. The next readout, EMBRACE, will decide whether the program is a single strong trial or a reproducible effect. For the field, the trial is the strongest evidence yet that a psilocybin-derived drug can produce a clinically meaningful effect in a large adjunctive-depression study. For investors, the gap between the data and the stock price is the thing to explain.

Primary sources

  1. Helus Pharma, "Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder," Nov. 16, 2026 (GlobeNewswire).
  2. Reuters, "Helus Pharma's psychedelic depression drug succeeds in late-stage study," Nov. 16, 2026 (via Yahoo News).
  3. StreetInsider, "Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study," Nov. 16, 2026.